CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

Donata Hoffmann, Björn Corleis, Susanne Rauch, Nicole Roth, Janine Mühe, Nico Joel Halwe, Lorenz Ulrich, Charlie Fricke, Jacob Schön, Anna Kraft, Angele Breithaupt, Kerstin Wernike, Anna Michelitsch, Franziska Sick, Claudia Wylezich, Bernd Hoffmann, Moritz Thran, Andreas Thess, Stefan O. Mueller, Thomas C. Mettenleiter, Benjamin Petsch, Anca Dorhoi () and Martin Beer ()
Additional contact information
Donata Hoffmann: Friedrich-Loeffler-Institut
Björn Corleis: Friedrich-Loeffler-Institut
Susanne Rauch: CureVac AG
Nicole Roth: CureVac AG
Janine Mühe: CureVac AG
Nico Joel Halwe: Friedrich-Loeffler-Institut
Lorenz Ulrich: Friedrich-Loeffler-Institut
Charlie Fricke: Friedrich-Loeffler-Institut
Jacob Schön: Friedrich-Loeffler-Institut
Anna Kraft: Friedrich-Loeffler-Institut
Angele Breithaupt: Friedrich-Loeffler-Institut
Kerstin Wernike: Friedrich-Loeffler-Institut
Anna Michelitsch: Friedrich-Loeffler-Institut
Franziska Sick: Friedrich-Loeffler-Institut
Claudia Wylezich: Friedrich-Loeffler-Institut
Bernd Hoffmann: Friedrich-Loeffler-Institut
Moritz Thran: CureVac AG
Andreas Thess: CureVac AG
Stefan O. Mueller: CureVac AG
Thomas C. Mettenleiter: Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health
Benjamin Petsch: CureVac AG
Anca Dorhoi: Friedrich-Loeffler-Institut
Martin Beer: Friedrich-Loeffler-Institut

Nature Communications, 2021, vol. 12, issue 1, 1-7

Abstract: Abstract The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-24339-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24339-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-24339-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().